Sutro Biopharma, Inc. (NASDAQ: STRO) announced the termination of its Open Market Sale Agreement with Jefferies LLC, effective March 23, 2026. This decision comes as the company aims to streamline its operations and focus on its clinical programs. The termination means that Sutro will not offer or sell any additional common shares under this agreement. In conjunction with this announcement, Sutro reported its financial results for the year ended December 31, 2025, revealing a revenue of $102.5 million, a significant increase from $62.0 million in 2024, primarily driven by collaborations with Astellas and Ipsen. The company also highlighted its cash position, with cash, cash equivalents, and marketable securities totaling $141.4 million as of December 31, 2025. This financial stability is expected to support Sutro's ongoing clinical trials and operational initiatives, extending its cash runway into at least the second quarter of 2028. Sutro's CEO, Jane Chung, expressed optimism about the company's prospects, emphasizing the potential of their proprietary antibody-drug conjugate platform and the progress of their clinical trials, including the Phase 1 trial of STRO-004. The company is also advancing its dual-payload program targeting PTK7, STRO-227, with an IND submission anticipated in 2026. Overall, while the termination of the sales agreement may raise concerns about liquidity, the strong revenue growth and solid cash position suggest a positive outlook for Sutro's future endeavors.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.